NIKKEI 225
38,179.46 -49.64 (-0.13%) HANG SENG
19,115.06 +151.36 (+0.80%) CRUDE OIL
79.14 +0.02 (+0.03%) GOLD FUTURES
2,343.60 +0.60 (+0.03%) DOW
39,431.51 -81.29 (-0.21%) Bitcoin GBP
50,122.20 +1,213.20 (+2.48%)
MRK Dec 2025 165.000 call
| Previous close | 3.2500 |
| Open | 3.5000 |
| Bid | 3.4000 |
| Ask | 3.7500 |
| Strike | 165.00 |
| Expiry date | 2025-12-19 |
| Day's range | 3.5000 - 3.5000 |
| Contract range | N/A |
| Volume | |
| Open interest | 19 |
BenzingaMerck Halts Skin Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma Treatment
Monday, Merck & Co Inc (NYSE:MRK) announced the discontinuation of the vibostolimab and pembrolizumab coformulation arm of the Phase 3 KeyVibe-010 trial. The trial evaluates the investigational coformulation of vibostolimab and Keytruda (pembrolizumab) compared to Keytruda alone as adjuvant treatment for patients with resected high-risk melanoma (Stage IIB-IV). Also Read: Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook. Data from a pre-planned analysis showed tha
Business WireMerck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma
RAHWAY, N.J., May 13, 2024--Merck Update on KeyVibe-010 Evaluating Coform of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients W/ Resected High-Risk Melanoma
Simply Wall St.Merck's (NYSE:MRK) investors will be pleased with their notable 90% return over the last three years
By buying an index fund, investors can approximate the average market return. But if you pick the right individual...
